Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan.
World J Surg Oncol. 2024 May 11;22(1):129. doi: 10.1186/s12957-024-03405-6.
Colorectal cancer (CRC) presents with varying prognoses, and identifying factors for predicting metastasis and outcomes is crucial. Perineural invasion (PNI) is a debated prognostic factor for CRC, particularly in stage I-III patients, but its role in guiding adjuvant chemotherapy for node-positive colon cancer remains uncertain.
We conducted a single-center study using data from the Colorectal Section Tumor Registry Database at Chang Gung Memorial Hospital, Taiwan. This prospective study involved 3,327 CRC patients, 1,536 of whom were eligible after application of the exclusion criteria, to investigate the prognostic value of PNI in stage I-III patients and its predictive value for node-positive/negative cancer patients receiving adjuvant chemotherapy. Propensity score matching (PSM) was used to minimize selection bias, and follow-up was performed with standardized procedures.
PNI-positive (PNI+) tumors were associated with higher preoperative CEA levels and more frequent adjuvant chemotherapy. After PSM, PNI + tumors were associated with marginally significantly lower 5-year disease-free survival (DFS) and significantly lower overall survival (OS) rates in stages III CRC. However, no significant differences were observed in stages I and II. Subgroup analysis showed that among PNI + tumors, only poorly differentiated tumors had higher odds of recurrence. PNI did not predict outcomes in node-negative colon cancer. Adjuvant chemotherapy benefited PNI + patients with node-positive but not those with node-negative disease.
Our study indicates that PNI is an independent poor prognostic factor in stage III colon cancer but does not predict outcomes in node-negative disease. Given the potential adverse effects of adjuvant chemotherapy, our findings discourage its use in node-negative colon cancer when PNI is present.
结直肠癌(CRC)的预后存在差异,确定预测转移和结局的因素至关重要。神经周围侵犯(PNI)是 CRC 的一个有争议的预后因素,特别是在 I-III 期患者中,但在指导淋巴结阳性结肠癌的辅助化疗方面其作用仍不确定。
我们使用台湾长庚纪念医院结直肠科肿瘤登记数据库中的数据进行了一项单中心研究。这项前瞻性研究涉及 3327 例 CRC 患者,应用排除标准后,有 1536 例符合条件,以调查 PNI 在 I-III 期患者中的预后价值及其对接受辅助化疗的淋巴结阳性/阴性癌症患者的预测价值。采用倾向评分匹配(PSM)最小化选择偏倚,并采用标准化程序进行随访。
PNI 阳性(PNI+)肿瘤与术前 CEA 水平升高和更频繁的辅助化疗相关。经过 PSM 后,PNI+肿瘤与 III 期 CRC 的 5 年无病生存率(DFS)略有显著降低和总生存率(OS)显著降低相关。但在 I 期和 II 期未观察到显著差异。亚组分析显示,在 PNI+肿瘤中,只有低分化肿瘤的复发风险更高。PNI 不能预测淋巴结阴性结肠癌的结局。辅助化疗对淋巴结阳性但对淋巴结阴性疾病的 PNI+患者有益。
我们的研究表明,PNI 是 III 期结肠癌的独立不良预后因素,但不能预测淋巴结阴性疾病的结局。鉴于辅助化疗可能产生的不良影响,当 PNI 存在时,我们不鼓励在淋巴结阴性结肠癌中使用辅助化疗。